^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EZH2 mutation

    i
    Entrez ID:
    2146
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (ETCTN 10183) (NCT03854474)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    11/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    PD-L1 • PD-1
    |
    EZH2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)
    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (P30CA016672) (NCT03383575)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/17/2018
    Primary completion :
    02/28/2027
    Completion :
    02/28/2027
    TP53 • IDH2 • RUNX1 • ASXL1
    |
    IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation
    |
    azacitidine • Idhifa (enasidenib)
    Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma (VALYM) (NCT04842877)
    Phase 2
    The Lymphoma Academic Research Organisation
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    06/11/2021
    Primary completion :
    12/03/2024
    Completion :
    10/01/2026
    SLC1A5
    |
    EZH2 mutation
    |
    Ezharmia (valemetostat)
    Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1) (NCT04224493)
    Phase 3
    Epizyme, Inc.
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    06/11/2020
    Primary completion :
    03/01/2026
    Completion :
    03/01/2029
    EZH2
    |
    EZH2 mutation
    |
    Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)
    A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation (Mandolin) (NCT06068881)
    Phase 2
    Epizyme, Inc.
    Not yet recruiting
    Last update posted :
    06/03/2024
    Initiation :
    09/02/2024
    Primary completion :
    09/28/2027
    Completion :
    09/28/2027
    EZH2
    |
    EZH2 mutation • EZH2 wild-type
    |
    Tazverik (tazemetostat)
    Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome (NCT03047993)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/14/2024
    Initiation :
    11/15/2017
    Primary completion :
    03/16/2023
    Completion :
    03/16/2023
    TP53 • IDH1 • IDH2 • RUNX1 • ASXL1
    |
    RUNX1 mutation • ASXL1 mutation • EZH2 mutation
    |
    azacitidine • telaglenastat (CB-839)
    Evaluate the Safety and Clinical Activity of HH2853 (NCT04390737)
    Phase 1/2
    Haihe Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    09/08/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    ARID1A • BAP1
    |
    ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation
    |
    HH2853
    Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (ETCTN 10500) (NCT05627245)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    03/01/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    EZH2
    |
    RAS wild-type • EZH2 mutation • EZH2 wild-type
    |
    Tazverik (tazemetostat) • Beleodaq (belinostat)
    Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (NCT04659616)
    Phase 1
    OHSU Knight Cancer Institute
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    01/14/2021
    Primary completion :
    08/01/2025
    Completion :
    02/01/2026
    TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation
    |
    cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)
    Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    03/23/2018
    Primary completion :
    12/01/2025
    Completion :
    03/01/2026
    IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
    Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis (ALLO-BAT) (NCT04217356)
    Phase N/A
    University Health Network, Toronto
    Recruiting
    Last update posted :
    03/22/2024
    Initiation :
    08/05/2020
    Primary completion :
    08/05/2025
    Completion :
    02/05/2026
    TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR
    |
    TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation
    |
    Jakafi (ruxolitinib) • hydroxyurea
    A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) (NCT04872543)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    03/01/2024
    Initiation :
    04/29/2021
    Primary completion :
    04/01/2026
    Completion :
    04/01/2026
    SUZ12
    |
    EZH2 mutation
    |
    Inqovi (decitabine/cedazuridine)
    Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas (NCT05415098)
    Phase 1
    Ascentage Pharma Group Inc.
    Recruiting
    Last update posted :
    11/16/2022
    Initiation :
    09/30/2022
    Primary completion :
    09/30/2024
    Completion :
    09/30/2025
    SMARCB1
    |
    EZH2 mutation
    |
    APG-5918
    A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms (NCT03603951)
    Phase 1
    Jiangsu HengRui Medicine Co., Ltd.
    Recruiting
    Last update posted :
    04/29/2022
    Initiation :
    08/14/2018
    Primary completion :
    02/14/2023
    Completion :
    08/14/2023
    BCL2 • BCL6
    |
    EZH2 mutation
    |
    SHR-2554